Imeglimin HCl | CAS#775351-61-6 | phosphorylation blocker

MedKoo Cat#: 563638 | Name: Imeglimin HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Imeglimin HCl is an oxidative phosphorylation blocker, inhibiting hepatic gluconeogenesis, increasing muscle glucose uptake, and restoring normal insulin secretion.

Chemical Structure

Imeglimin HCl

CAS#775351-61-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 563638

Name: Imeglimin HCl

CAS#: 775351-61-6 (HCl)

Chemical Formula: C6H14ClN5

Exact Mass: 191.0938

Molecular Weight: 191.66

Elemental Analysis: C, 37.60; H, 7.36; Cl, 18.50; N, 36.54

Price and Availability

Size	Price	Availability
10mg	USD 250.00	2 Weeks
50mg	USD 650.00	2 Weeks
100mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

775351-61-6 (HCl) 775351-65-0 (free base)

Synonym

Imeglimin hydrochloride; Imeglimin HCl; EMD387008 hydrochloride; EMD387008 HCl;

IUPAC/Chemical Name

(R)-N2,N2,6-trimethyl-3,6-dihydro-1,3,5-triazine-2,4-diamine hydrochloride

InChi Key

UXHLCYMTNMEXKZ-PGMHMLKASA-N

InChi Code

InChI=1S/C6H13N5.ClH/c1-4-8-5(7)10-6(9-4)11(2)3;/h4H,1-3H3,(H3,7,8,9,10);1H/t4-;/m1./s1

SMILES Code

NC1=N[C@@H](C)N=C(N(C)C)N1.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 191.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kvapil M. [Promising molecules for treatment of hyperglycemia in patients with type 2 diabetes]. Vnitr Lek. 2016 Fall;62(11 Suppl 4):S67-71. Review. Czech. PubMed PMID: 27921428. 2: Detaille D, Vial G, Borel AL, Cottet-Rouselle C, Hallakou-Bozec S, Bolze S, Fouqueray P, Fontaine E. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016 Jan 18;2:15072. doi: 10.1038/cddiscovery.2015.72. eCollection 2016. PubMed PMID: 27551496; PubMed Central PMCID: PMC4979505. 3: Perry RJ, Cardone RL, Petersen MC, Zhang D, Fouqueray P, Hallakou-Bozec S, Bolze S, Shulman GI, Petersen KF, Kibbey RG. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E461-70. doi: 10.1152/ajpendo.00009.2016. Epub 2016 Jul 12. PubMed PMID: 27406738; PubMed Central PMCID: PMC5005968. 4: Scheen AJ. Investigational insulin secretagogues for type 2 diabetes. Expert Opin Investig Drugs. 2016;25(4):405-22. doi: 10.1517/13543784.2016.1152260. Epub 2016 Feb 27. Review. PubMed PMID: 26881467. 5: Vuylsteke V, Chastain LM, Maggu GA, Brown C. Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes. Drugs R D. 2015 Sep;15(3):227-32. doi: 10.1007/s40268-015-0099-3. Review. PubMed PMID: 26254210; PubMed Central PMCID: PMC4561051. 6: Pacini G, Mari A, Fouqueray P, Bolze S, Roden M. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2015 Jun;17(6):541-5. doi: 10.1111/dom.12452. Epub 2015 Mar 25. PubMed PMID: 25694060. 7: Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM, Bernoud-Hubac N, Pais de Barros JP, Fontaine É, Acquaviva C, Hallakou-Bozec S, Bolze S, Vidal H, Rieusset J. Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015 Jun;64(6):2254-64. doi: 10.2337/db14-1220. Epub 2014 Dec 31. PubMed PMID: 25552598. 8: Fouqueray P, Pirags V, Diamant M, Schernthaner G, Lebovitz HE, Inzucchi SE, Bailey CJ. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care. 2014 Jul;37(7):1924-30. doi: 10.2337/dc13-2349. Epub 2014 Apr 10. PubMed PMID: 24722500. 9: Fouqueray P, Pirags V, Inzucchi SE, Bailey CJ, Schernthaner G, Diamant M, Lebovitz HE. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013 Mar;36(3):565-8. doi: 10.2337/dc12-0453. Epub 2012 Nov 16. PubMed PMID: 23160726; PubMed Central PMCID: PMC3579350. 10: Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012 Sep;14(9):852-8. doi: 10.1111/j.1463-1326.2012.01611.x. Epub 2012 May 16. PubMed PMID: 22519919.